BH
Brad Hively
Director

Brad Hively insider trades: Starling Oncology (STLN) stock buys and sales

Director, Starling Oncology Last trade Aug 21, 2026 20 Form 4 filings
$2.0M
Sold, last 12 months
2 sales
$0
Bought, last 12 months
0 buys
8
Open-market trades
since 2023
2
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Brad reports to the SEC

Open-market buys and sales

8 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 21, 2026STLN↓ Sell$1.9M
Dec 15, 2025TOI↓ Sell$50K
Aug 19, 2025TOI↓ Sell$82K
Jun 3, 2025TOI↓ Sell$5.7M
Mar 26, 2025TOI↑ Buy$9K
Dec 2, 2024TOI↑ Buy$50K
Nov 17, 2023TOI↓ Sell$56K
Nov 13, 2023TOI↓ Sell$119K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other STLN insiders

Open-market trades in the last 12 months

About Brad Hively's insider trades

Brad Hively is a director at Starling Oncology (STLN). Since Nov 13, 2023, Brad has reported 2 open-market purchases worth $59K and 6 sales worth $7.9M on SEC Form 4. In the last 12 months: 2 sales ($2.0M).

Their filings also include grants and awards (8 filings), shares returned to the company (5 filings), option exercises (3 filings), other transactions (2 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every STLN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.